.Pharmacolibrary.Drugs.ATC.B.B01AC19

Information

Beraprost is an orally active prostacyclin analog used primarily as a vasodilator for the treatment of pulmonary arterial hypertension (PAH) and peripheral arterial disease. It acts by inhibiting platelet aggregation and inducing vasodilation. While approved for use in Japan and some Asian countries, it is not currently approved by the US FDA or EMA.

Pharmacokinetics

Pharmacokinetic parameters reported in healthy adult volunteers after a single oral dose

References

1. Galiè, N, et al., & Branzi, A (2003). Prostanoids for pulmonary arterial hypertension. American journal of respiratory medicine : drugs, devices, and other interventions 2(2) 123–137. DOI:10.1007/BF03256644 PUBMED:https://pubmed.ncbi.nlm.nih.gov/14720012

2. Nakajo, I, et al., & Shiramoto, M (2021). Comparison of Pharmacokinetic Profiles of Beraprost Sustained Release in Japanese, Chinese, and Korean Healthy Adult Males. Clinical drug investigation 41(6) 549–555. DOI:10.1007/s40261-021-01031-8 PUBMED:https://pubmed.ncbi.nlm.nih.gov/33913081

Revisions

• 06/2025 initial generated model